Gene transfer of neurotrophic or antiangiogenic factors has been shown to improve photoreceptor survival in retinal degenerative disorders (that is retinitis pigmentosa) and to prevent neovascularization in retinal vascular diseases (that is age-related macular degeneration, diabetic retinopathy). Expression of such neurotrophic or antiangiogenic factors after gene transfer requires the use of a regulatory system to control transgene expression to avoid unwanted side effects in cases of overexpression. In a previous study, we demonstrated that rAAV-mediated gene transfer of the tetracycline-regulatable (tetR) system allows transgene regulation in the retina of nonhuman primates after intravenous administration of doxycycline (Dox). The purpose of this study was to evaluate oral administration of Dox to control transgene expression in the retina, since the pharmacokinetics after oral administration of the inducer drug represent a key factor when considering advancing to clinical trials. We report on the outcome of this evaluation and demonstrate that oral administration of Dox at a dose that is clinically used in humans (5 mg kg À1 per day) is capable to continuously induce transgene expression in all macaques tested for 6 months. Moreover, control of transgene expression persists up to 4 years post-subretinal injection, with maximal induced levels of transgene product remaining stable over time.
Retinal degenerative diseases, such as retinitis pigmentosa (RP), are triggered by mutations in a variety of genes and by environmental factors. 1 Hence, there is great interest in developing a generally applicable survival factor therapy that targets not the specific mutant gene, but rather alters the photoreceptor environment in a manner that promotes cell survival. The most promising neurotrophic factor, ciliary neurotrophic factor, was studied in different mouse models of retinal degeneration after rAAV-mediated gene transfer, [2] [3] [4] [5] [6] and was used in preclinical studies via an encapsulated cell-based delivery system, resulting in photoreceptor protection in the retina of the pde6b rcd1 dog model. 7 Recently, a similar cell-based delivery protocol was used in a phase I clinical safety trial in six patients, 8 with no negative side effects observed. In contrast, intraocular ciliary neurotrophic factor expression using rAAV2-mediated gene delivery in wild type, Prph Rd2/Rd2 , and P216L rds/ peripherin mice resulted in a significant decrease of photoreceptor function. 5 Furthermore, direct intraocular injection of ciliary neurotrophic factor has been shown to negatively influence the phototranscription machinery by decreasing rhodopsin production and increasing intracellular arrestin levels. 9 These effects were fully reversible. It is therefore possible, that ciliary neurotrophic factor has a narrow therapeutic window and that overproduction needs to be avoided. Hence, a key issue for successful photoreceptor protection using such neurotrophic factors is the ability to regulate transgene expression.
Ocular neovascularization in diseases such as agerelated macular degeneration or diabetic retinopathy, is caused by hypoxia in retinal tissue and subsequent overexpression of proangiogenic factors (that is VEGF). 10, 11 Treatment strategies therefore aim to delay or totally prevent the onset of neovascularization by retinal transfer of antiangiogenic factors, such as PEDF or VEGF antagonists. 12 Recently, several synthetic anti-VEGF molecules such as pegaptanib, 13, 14 Ranibizumab, 15, 16 and Bevacicumab 17 have been used to inhibit choroidal (CNV) or retinal (RNV) neovascularization by repeated intraocular injection. Given that such a treatment regimen is likely to be indefinite, repeated injections may be associated with complications due to inflammation or an increased risk of retinal detachment. 18 Recombinant AAV-mediated gene transfer of antiangogenic factors to the retina has been shown to inhibit neovascularization in different rodent models of CNV and RNV, using the cDNAs for genes such as PEDF, [19] [20] [21] sFLT1,  22-24 VEGF exons 6-7,  25 endostatin and  Timp3  20 or different active domains of angiostatin.   19 However, it is not clear whether long-term inhibition of angiogenesis after gene transfer is safe, since angiogenesis is also an important survival mechanism for endothelial cells and neurons. 26, 27 Regulated expression of antiangiogenic proteins after gene transfer would help to avoid the unwanted side effects of overexpression and subsequent long-term inhibition of angiogenesis.
In our previous study, we demonstrated that intravenous administration of doxycycline (Dox) in nonhuman primates injected subretinally with AAV.TetOn.epo vectors allowed regulation of transgene expression in the retina. 28 The purpose of this study was to determine the sensitivity of the tetR system for different doses of Dox, and to evaluate the efficacy of oral administration of Dox to induce transgene expression, as this represents a key factor for any clinical application involving neurotrophic and antiangiogenic factors.
In this study, Dox-mediated transgene expression was evaluated in a total of five macaques: P5.1 through P5.3, which had been injected with rAAV2/5, and P4.1 and P4.2, which had been injected with rAAV2/4 ( Table 1 ). All macaques received AAV unilaterally in the right retina except for P5.3 that was treated in both eyes (P5.3L and P5.3R). Upon induction of transgene expression by a 3-day Dox pulse (10 mg kg À1 ) given intravenously, average peak EPO levels obtained in the anterior chamber fluid (a.c.f.) were 500-1000 and 100 mU ml (Figures 1 and 2) . The difference in EPO levels between the two vectors is ostensibly due to the cellular tropism of the different vectors, since rAAV2/5 vectors target both, the RPE and the photoreceptors, while the rAAV2/4 vectors target specifically the RPE. 31 Initially, we evaluated the sensitivity of the tetR system for different doses of Dox using a 3-day intravenous administration induction regimen. When administered 10 mg of Dox per day, macaque P5.1 showed average maximum EPO levels of 1077 mU ml À1 during the first four inductions (Figure 1 , indicated by a dashed grey horizontal line).
Intravenous administration in the same individual of 5 and 2.5 mg kg À1 of Dox resulted in EPO levels at 94% of those reached by 10 mg (1014 and 1007 mU ml , is still sufficient to induce EPO expression to levels well above background. These dose-response results are in agreement with the previous observation in the rat retina using the tetR system, where inductions were performed using 200 mM (5 mg kg
À1
) of Dox administered in drinking water, and as little as 2 mM (0.05 mg kg À1 ) or 1% of the original Dox concentration was sufficient to induce a minimal amount of GFP expression. 32 Importantly, for the last induction of P5.1 at 4 years post-injection, Dox was administered at the original dose of 10 mg kg À1 per day and maximum EPO expression in the retina reached original levels obtained during the first four inductions (1075 mU ml À1 ). These results demonstrate that: (i) the Dox-regulatable system in the retina is not shut down by the immune system as in the nonhuman primate skeletal muscle; 33 (ii) the expression of EPO in the retina is dependent on the dose of Dox administered; and (iii) maximally induced levels of EPO are consistent over time, having not diminished over a 4-year period.
For clinical translation, intravenous administration of Dox is not ideal, as daily injections over several weeks or months are not appropriate. Hence, we evaluated the possibility to induce transgene expression by oral administration of Dox.
First, we tested the capacity of orally administered Dox to induce EPO expression in short-term cycles. Primates P5.2, P5.3, P4.1 and P4.2, which were given Dox by intravenous injections during the first six induction cycles, were then given Dox hidden in dry fruits during the 7th and 8th induction for 3 days at doses of five and 10 mg kg À1 , respectively (Figure 2 ). Both oral induction cycles resulted in EPO expression characterized by similar induction kinetics as seen with intravenous administration, that is a peak at 48 h post-induction and rapid decline to baseline levels within 10 days of withdrawal of Dox. The concentrations of EPO after oral administration of 10 mg kg À1 of Dox were roughly comparable to the average peak EPO levels obtained after intravenous induction with 10 mg kg À1 (Figure 2 , indicated by a dashed grey line). ) and 66% (400 mU ml
) of EPO expression for the left and the right eye, respectively. Finally, P4.1 reached 66% (80 mU ml
) of EPO expression when compared to intravenous induction.
Concerning the different serotypes of AAV used in this study, both primates injected with the AAV serotype 5, P5.2 and P5.3, showed no difference in EPO expression when they were orally induced with 5 mg kg À1 versus 10 mg kg À1 (Figure 2 ). In contrast, the two primates injected with AAV serotype 4, P4.1 and P4.2, showed a 25-50% reduction of EPO expression when orally induced with 5 mg kg
À1 . These results demonstrate for the first time, that oral administration of Dox results in EPO expression in the retina of nonhuman primates, with similar kinetics compared to intravenous administration. Moreover, Dox can be orally administered at doses that are clinically relevant in humans (5 mg kg À1 per day), 34 to induce a strong expression of EPO. The fact that the pharmacokinetics of Dox in humans and nonhuman primates are similar 35 suggests that the regulation of transgene expression using this TetR system in human will be equally efficient.
Decreased peak EPO levels not associated with vector capsid origin, as seen in some but not all primates may result from individual differences in the oral uptake of Dox and variability in the immediate presence of Dox in the retina.
Until now, inductions lasting more than 3 days were difficult to perform, as intravenous injections required daily anaesthesia of the animals. To mimic a therapeutic intervention, we evaluated induction of EPO expression in the retina for a longer period. Two primates (P5.2 and P4.2) were induced for 3 weeks by oral administration of Dox at 10 mg kg À1 (Figure 2, 9th induction) . EPO levels in the a.c.f. increased during the first week and reached a peak at 1200 mU ml À1 for P5.2 and 80 mU ml À1 for P4.2. For P5.2, the peak obtained was 130% of the maximum EPO expression during short-term inductions, whereas for P4.2, the peak of EPO levels corresponded to 100% of the short-term induction pattern. Upon Dox withdrawal, EPO levels in the a.c.f. decreased to baseline levels within 10 days, according to what has been observed during short-term inductions. Figure 1 Intravenous injection of Dox allows dose-dependent expression of EPO in the retina after subretinal delivery of AAV2/ 5.CAG.TetOn.epo in macaque P5.1. Generation of expression cassettes encoding EPO (P tet -1-mEpo-WPRE-pA) and the transactivator rtTA-M2 (CAG-rtTA-M2-pA) was described previously. 29 The two expression cassettes, flanked by two AAV2 ITRs, were encapsidated into AAV5 and AAV4 shells, producing two vectors, AAV2/5.CAG.TetOn.Epo, and AAV2/4.CAG.TetOn.Epo respectively. The rAAV titres were determined by dot blot and expressed as vector genomes(vg) per ml. 30 Primates were purchased from BioPrim, Baziège, France. All animals were cared for in accordance with the ARVO statement for the use of animals in ophthalmic and vision research. Subretinal injections were performed via a transvitreal approach under isoflurane gas anaesthesia as described previously. 31 Volumes injected were between 90 and 150 ml and vector titres were 2 Â 10 11 vg ml À1 for AAV-2/4 and 5 Â 10 11 and 1 Â 10 12 vg ml À1 for AAV-2/5 ( Table 1 ). The protocol was approved by the Institutional Animal Care and Use Committee of the University of Nantes. All subretinal injections were performed unilaterally on the right eye (except for macaque P5.3, who was injected into both eyes). In P5.1, induction of EPO expression consisted of a 3-day Dox pulse (Doxycycline-ratiopharm SF, Ratiopharm) given intravenously. Sampling of the anterior chamber fluid was performed as follows. Primates were anaesthetized with an intramuscular (i.m.) injection of ketamine (Imalgène, Rhone Merieux, France) and Medetomidin (Domitor, Pfizer), and a 27-gauge epicranial cannula was used to penetrate the cornea. EPO concentration was measured by enzyme-linked immunosorbent assay (Quantikine IVD; R&D Systems) and reported in mU ml 
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Altogether, this medium term induction protocol demonstrated the capacity of the tetR system to drive transgene expression for 3 weeks with rapid induction and de-induction kinetics.
Expression of neurotrophic or antiangiogenic factors in the retina may have to be induced over a long-time period to cause the desired effect. Therefore, we evaluated the capacity of the tetR system to continuously induce transgene expression over 6 months by oral administration. We decided to use a dose of 5 mg kg À1 (instead of 10 mg kg
À1
) for the long-term induction protocol, as this avoids the risk of side effects due to elevated daily Dox intake.
Four primates, P5.2, P5.3, P4.1 and P4.2, were induced for 6 months (Figure 2, 10th induction) . Within 48 h, EPO levels in the a.c.f. reached a maximum concentration and remained stable for the duration of the experiment (indicated by a continuous grey line in Figure 2 ). The initial decline of EPO concentration 1 week after induction of P4.2 was due to a compliance issue of oral Dox administration seen in this particular primate, which was solved after 3 weeks. Upon Dox withdrawal, EPO levels declined to baseline levels within 10 days, identical to the de-induction kinetics of short-and medium-term induction protocols.
Dox is deposited in bones, teeth and other tissues after long-term administration, which would make it conceivable that Dox may be released slowly into the circulation once the drug is withdrawn at the end of the experiment. 34 However, the rapid decline of EPO expression at the end of the 6 months induction period indicates that Dox was not stored and slowly released by bones and other tissues after the long-term induction. This pharmacokinetic pattern at the retinal level is obviously an important specificity for future gene therapy clinical trials.
The oral dose of Dox used (5 mg kg À1 ) corresponds to the upper limit of the therapeutic dose given to patients for antibiotic treatment, which yet remains well tolerated. 34 None of the four primates used in the long-term induction protocol showed any adverse side effect due to continuous Dox administration or long-term EPO expression in the retina. Biochemical markers obtained every month for renal (creatinin, urea) and liver (ALAT, ASAT, gGT, AP) functions showed no increase and total reticulocyte and red blood cell counts remained normal as well (data not shown). Regular clinical evaluation of fundus and cornea in all primates did not identify abnormalities due to the presence of high intraocular EPO concentrations.
In conclusion, we demonstrated, here, for the first time that oral administration of Doxycycline: (i) is about as efficient as the intravenous delivery of Dox; (ii) can induce stable EPO expression in the retina over a 6-month period; and (iii) is not associated with detectable side effects due to either the long-term Dox administration or the elevated local EPO concentrations.
Finally, a last short-term (3 days) induction by oral administration of Dox (Figure 2, 11th induction) was performed in the four macaques, P5.2, P5.3, P4.1, P4.2. They all displayed levels of EPO expression similar to those obtained during the 7th induction. These results indicate that the tetR system retains its capacity to tightly regulate transgene expression even after a 6-month permanent Dox induction.
For all macaques used in this study, no decline of maximum induced transgene expression was observed over the 4 years (P5.1) or 2.5 years (all remaining macaques) post-AAV administration. This is in contrast to what has been observed in gene transfer studies targeting primate skeletal muscle. In the muscle, after an initial augmentation and a peak of transgene expression at 3 months post-injection (hyper-responsive phase), transgene expression stabilized from 6 months to 1 year post-injection at 50% of the original levels 29, 36 (P Moullier, unpublished data). Loss of unstable episomal structures or local immune responses, that destroy some but not all transduced cells, have been proposed to explain this decline of transgene expression in primate skeletal muscle.
In this study, we demonstrate for the first time that oral administration of Dox efficiently regulates transgene expression in the retina of nonhuman primates. In view of clinical applications, we show that transgene expression can be induced continuously for 6 months resulting in stable levels of protein in the retina. Moreover, this capacity of the tetR system for stringent regulation of transgene expression persists long-term (up to 4 years post-subretinal injection of AAV.TetOn.epo vector).
These results clearly demonstrate the potential for the development of a neurotrophic or antiangiogenic gene therapy strategy using the tetR system in the retina.
